 |
|
|
| |
Therapeutic Vaccine JNJ-0535 Induces a Strong
HBV-specific T-cell Response in Healthy Adults
and a Modest Response in Chronic HBV-infected Patients
VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits
|
| |
| |
EASL: Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study - (06/25/22)
EASL 2022 June 22-26 London
An De Creus,1 Leen Slaets,1 Bart Fevery,1 Ellen Van Gulck,1 Linghua Zhou,1 Tim Van De Parre,1 Celine Van Den Broeke,1 Dessislava Dimitrova,2 Isabelle Lonjon-Domanec,1 David Blue,3 Pieter Van Remoortere,2 Stefan Bourgeois,4 Patrick Kennedy,5 Sandra De Meyer1
1Janssen Research & Development, Beerse, Belgium; 2Janssen Research & Development, LLC, Titusville, NJ, USA; 3Janssen Biopharma, Inc., South San Francisco, CA, USA; 4Hospital Network Antwerp (ZNA), Antwerp, Belgium; 5Barts and The London School of Medicine and Dentistry, London, UK.
|
| |
|
|
|
|
|
